ADVENZYMES
Advanced Enzyme Technologies Limited
Each stock's 10,000-path forecast, rendered as light.
Advanced Enzyme Technologies Limited (ADVENZYMES) Stock Analysis & Case Study
Is ADVENZYMES a good buy? The data-driven verdict.
Advanced Enzyme Technologies Limited (ADVENZYMES) trades at ₹324,on the numbers it mixed signals, a Downstox Snapshot Score of 49/100.
On the numbers, Advanced Enzyme Technologies Limited (ADVENZYMES) mixed signals, a Downstox Snapshot Score of 49/100, weighing fairly valued at 23.0× earnings, ROE of 10.2%, a 53% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
ADVENZYMES fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How ADVENZYMES ranks against the 2,373 companies in our screener
- ADVENZYMES's market cap of 3,632 Cr ranks in the 60th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ADVENZYMES's book value of ₹146 ranks in the 63rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ADVENZYMES's promoter holding of 43.2% ranks in the 20th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ADVENZYMES's 3-year profit (PAT) growth of 12.0% ranks in the 45th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ADVENZYMES's 3-year revenue growth of 11.0% ranks in the 53rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ADVENZYMES's debt-to-equity ratio of 0.02x is lower than 94% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is ADVENZYMES overvalued? ADVENZYMES P/E vs peers
ADVENZYMES trades at 23.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
ADVENZYMES share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of ADVENZYMES history (1%/yr drift, 40%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| ADVENZYMES 2027 | ₹199 | ₹333 | ₹555 | +3% |
| ADVENZYMES 2028 | ₹166 | ₹341 | ₹700 | +5% |
| ADVENZYMES 2029 | ₹145 | ₹349 | ₹842 | +8% |
| ADVENZYMES 2030 | ₹128 | ₹358 | ₹1,005 | +10% |
| ADVENZYMES 2031 | ₹118 | ₹367 | ₹1,143 | +13% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability ADVENZYMES goes up, or doubles?
The bull case for ADVENZYMES
- ADVENZYMES's P/E of 23.0x is lower than 57% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹842.
The bear case & risks
- ADVENZYMES's return on equity of 10.2% ranks in the 51st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹145.
ADVENZYMES volatility & expected range, how bumpy is the ride?
Over the last 9.8 years ADVENZYMES compounded at 1%/year with annualized volatility of 40%. That volatility implies a 1-year 80% range of ₹199-₹555, the honest backbone behind any single price target.
ADVENZYMES price forecast, the full 60-month probability fan
ADVENZYMES price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds ADVENZYMES hits common targets within the simulated horizon?
Full multi-horizon detail on the ADVENZYMES price target & forecast page.
ADVENZYMES Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. ADVENZYMES scores 6/8, mixed financial health.
ADVENZYMES MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy ADVENZYMES with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 33.27% | 3.0× |
| Groww | 33.35% | 3.0× |
| DhanCHEAPEST | 33.27% | 3.0× |
| Kotak Neo | 34.97% | 2.9× |
| Paytm Money | 33.46% | 3.0× |
| Pocketful | 33.67% | 3.0× |
| Anand Rathi | 33.27% | 3.0× |
| Bajaj Broking | 40.00% | 2.5× |
| Share India | 33.35% | 3.0× |
Compare every broker on the ADVENZYMES MTF page.
About Advanced Enzyme Technologies Limited: sector, index & market-cap context
Advanced Enzyme Technologies Limited (ADVENZYMES) is a small-cap NSE-listed company, with a market capitalisation of ₹3,632 Cr. See more stocks on our screener.
How the ADVENZYMES Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Advanced Enzyme Technologies Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ADVENZYMES analysis, FAQs
Is Advanced Enzyme Technologies Limited (ADVENZYMES) a good buy?
On the numbers, Advanced Enzyme Technologies Limited (ADVENZYMES) mixed signals, a Downstox Snapshot Score of 49/100, weighing fairly valued at 23.0× earnings, ROE of 10.2%, a 53% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is ADVENZYMES overvalued or undervalued?
ADVENZYMES trades at 23.0× earnings, fairly valued versus the ~22× long-run Nifty average.
What is the ADVENZYMES share price target for 2031?
ADVENZYMES's probability-weighted 2031 median target is ₹367, with an 80% range of ₹118-₹1,143 (10,000-path Monte-Carlo).
What is the probability ADVENZYMES doubles in 5 years?
The modelled probability of ADVENZYMES reaching ₹649 (2×) within 5 years is 26%.
What is the bull case for ADVENZYMES?
ADVENZYMES's P/E of 23.0x is lower than 57% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in ADVENZYMES?
ADVENZYMES's return on equity of 10.2% ranks in the 51st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.